Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 67% of modeled bridge. Strengths: Net-to-Gross Ratio, Bed Count. Risks: Revenue per Bed. Risk-adjusted uplift: $1.1M (vs $1.6M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $596K | $596K | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $573K | $16K | $590K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $91K | $271K | $362K | $1.1M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $19K | $19K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 55.5% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $149K | $298K | $447K | $596K | $596K | $596K | $596K |
| Denial Rate Reduction | $0 | $147K | $295K | $442K | $590K | $590K | $590K | $590K |
| A/R Days Reduction | $0 | $121K | $242K | $362K | $362K | $362K | $362K | $362K |
| Clean Claim Rate | $0 | $10K | $19K | $19K | $19K | $19K | $19K | $19K |
| Cumulative | $0 | $427K | $853K | $1.3M | $1.6M | $1.6M | $1.6M | $1.6M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $1.6M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 92% / 26.4x | 97% / 29.7x | 101% / 33.0x | 103% / 34.6x | 105% / 36.3x |
| 9.0x | 87% / 23.1x | 92% / 26.0x | 96% / 29.0x | 98% / 30.4x | 100% / 31.9x |
| 10.0x | 83% / 20.5x | 87% / 23.1x | 91% / 25.7x | 93% / 27.1x | 95% / 28.4x |
| 11.0x | 79% / 18.3x | 83% / 20.7x | 87% / 23.1x | 89% / 24.3x | 91% / 25.5x |
| 12.0x | 75% / 16.5x | 80% / 18.7x | 84% / 20.9x | 86% / 22.0x | 87% / 23.1x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 67% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 2.2x, adding 6.3 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $541K | — | $541K | 1.8% |
| Year 1 | $557K | +$1.0M | $1.6M | 5.4% |
| Year 2 | $574K | +$1.6M | $2.1M | 7.2% |
| Year 3 | $591K | +$1.6M | $2.2M | 7.2% |
| Year 4 | $609K | +$1.6M | $2.2M | 7.3% |
| Year 5 | $627K | +$1.6M | $2.2M | 7.4% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $298K | $447K | $596K | $715K |
| Denial Rate Reductio | $295K | $442K | $590K | $708K |
| A/R Days Reduction | $181K | $272K | $362K | $435K |
| Clean Claim Rate | $10K | $14K | $19K | $23K |
| Total | $783K | $1.2M | $1.6M | $1.9M |
Peer Context — Where This Hospital Sits
Key metrics vs 31 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 1.8% | -26.4% | -1.6% | 6.0% | P61 |
| Net-to-Gross | 14.8% | 16.2% | 35.9% | 55.5% | P19 |
| Occupancy | 50.9% | 51.8% | 59.2% | 76.8% | P23 |
| Rev/Bed | $480K | $394K | $520K | $1.3M | P39 |
| Exp/Bed | $472K | $432K | $527K | $1.5M | P39 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.